Cytokine-based therapy for metastatic renal cell cancer
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 30 (3) , 589-600
- https://doi.org/10.1016/s0094-0143(03)00027-2
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Immunomodulatory Effects of Interleukin-2 and Interleukin-4 in Patients with MalignancyJournal of Immunotherapy, 1996
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- Cloning of the γ Chain of the Human IL-2 ReceptorScience, 1992
- Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanomaEuropean Journal Of Cancer, 1992
- Renal Cell Carcinoma Treated with Continuous-Infusion Interleukin-2 with Ex Vivo-Activated Killer CellsJournal of Immunotherapy, 1992
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell CarcinomaJournal of Immunotherapy, 1991
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985